Literature DB >> 29182606

Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.

Matthew D Galsky1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29182606     DOI: 10.1038/nrurol.2017.199

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Authors:  Joaquim Bellmunt; Ronald de Wit; David J Vaughn; Yves Fradet; Jae-Lyun Lee; Lawrence Fong; Nicholas J Vogelzang; Miguel A Climent; Daniel P Petrylak; Toni K Choueiri; Andrea Necchi; Winald Gerritsen; Howard Gurney; David I Quinn; Stéphane Culine; Cora N Sternberg; Yabing Mai; Christian H Poehlein; Rodolfo F Perini; Dean F Bajorin
Journal:  N Engl J Med       Date:  2017-02-17       Impact factor: 91.245

2.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

Authors:  Padmanee Sharma; Margitta Retz; Arlene Siefker-Radtke; Ari Baron; Andrea Necchi; Jens Bedke; Elizabeth R Plimack; Daniel Vaena; Marc-Oliver Grimm; Sergio Bracarda; José Ángel Arranz; Sumanta Pal; Chikara Ohyama; Abdel Saci; Xiaotao Qu; Alexandre Lambert; Suba Krishnan; Alex Azrilevich; Matthew D Galsky
Journal:  Lancet Oncol       Date:  2017-01-26       Impact factor: 41.316

Review 3.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Authors:  Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora N Sternberg; Dean F Bajorin; Joaquim Bellmunt
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

4.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

5.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

6.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Authors:  A Gordon Robertson; Jaegil Kim; Hikmat Al-Ahmadie; Joaquim Bellmunt; Guangwu Guo; Andrew D Cherniack; Toshinori Hinoue; Peter W Laird; Katherine A Hoadley; Rehan Akbani; Mauro A A Castro; Ewan A Gibb; Rupa S Kanchi; Dmitry A Gordenin; Sachet A Shukla; Francisco Sanchez-Vega; Donna E Hansel; Bogdan A Czerniak; Victor E Reuter; Xiaoping Su; Benilton de Sa Carvalho; Vinicius S Chagas; Karen L Mungall; Sara Sadeghi; Chandra Sekhar Pedamallu; Yiling Lu; Leszek J Klimczak; Jiexin Zhang; Caleb Choo; Akinyemi I Ojesina; Susan Bullman; Kristen M Leraas; Tara M Lichtenberg; Catherine J Wu; Nicholaus Schultz; Gad Getz; Matthew Meyerson; Gordon B Mills; David J McConkey; John N Weinstein; David J Kwiatkowski; Seth P Lerner
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

7.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Authors:  Arjun V Balar; Daniel Castellano; Peter H O'Donnell; Petros Grivas; Jacqueline Vuky; Thomas Powles; Elizabeth R Plimack; Noah M Hahn; Ronald de Wit; Lei Pang; Mary J Savage; Rodolfo F Perini; Stephen M Keefe; Dean Bajorin; Joaquim Bellmunt
Journal:  Lancet Oncol       Date:  2017-09-26       Impact factor: 41.316

8.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.

Authors:  Bishoy M Faltas; Davide Prandi; Scott T Tagawa; Ana M Molina; David M Nanus; Cora Sternberg; Jonathan Rosenberg; Juan Miguel Mosquera; Brian Robinson; Olivier Elemento; Andrea Sboner; Himisha Beltran; Francesca Demichelis; Mark A Rubin
Journal:  Nat Genet       Date:  2016-10-17       Impact factor: 38.330

9.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

  9 in total
  6 in total

1.  Surgery improves survival in bladder signet-ring cell carcinoma-a population-based study.

Authors:  Mohammed Alradhi; Mohammed Safi; Shenghua Tao; Abdullah Al-Danakh; Marwan Almoiliqy; Salem Baldi; Xiancheng Li
Journal:  Ther Adv Urol       Date:  2022-04-07

Review 2.  Overcoming biological barriers to improve solid tumor immunotherapy.

Authors:  Anvay Ukidve; Katharina Cu; Ninad Kumbhojkar; Joerg Lahann; Samir Mitragotri
Journal:  Drug Deliv Transl Res       Date:  2021-02-20       Impact factor: 4.617

3.  Fascin Inhibitors Decrease Cell Migration and Adhesion While Increase Overall Survival of Mice Bearing Bladder Cancers.

Authors:  Zhankui Zhao; Yufeng Wang; J Jillian Zhang; Xin-Yun Huang
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

Review 4.  Bladder Cancer: New Insights into Its Molecular Pathology.

Authors:  Kentaro Inamura
Journal:  Cancers (Basel)       Date:  2018-04-01       Impact factor: 6.639

Review 5.  Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data.

Authors:  Matteo Giulietti; Giulia Occhipinti; Alessandra Righetti; Massimo Bracci; Alessandro Conti; Annamaria Ruzzo; Elisabetta Cerigioni; Tiziana Cacciamani; Giovanni Principato; Francesco Piva
Journal:  Front Oncol       Date:  2018-10-12       Impact factor: 6.244

6.  Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment.

Authors:  Bo Fan; Alradhi Mohammed; Yuanbin Huang; Hong Luo; Hongxian Zhang; Shenghua Tao; Weijiao Xu; Qian Liu; Tao He; Huidan Jin; Mengfan Sun; Man Sun; Zhifei Yun; Rui Zhao; Guoyu Wu; Xiancheng Li
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.